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INTRODUCTION
Isocyanate chemicals are currently the most common causes
of occupational asthma worldwide and in Korea as well with
a prevalence of 2.9% to 13% in exposed workers (1). Long-
term follow-up studies of subjects with isocyanate asthma have
suggested that asthmatic symptoms may persist in some sub-
jects for months or years after work withdrawal (2-6). Our
previous study also demonstrated that 25 (61%) among 41
patients had persistent asthma symptoms after 5 yr’ follow-
up period, despite anti-asthmatic medications and complete
avoidance from exposure (7). 
Vascular endothelial growth factor (VEGF) is a multi-func-
tional cytokine, which plays a role in chronic airway inflam-
mation, angiogenesis and airway remodeling in bronchial
asthma (8-11). VEGF could increase vascular permeability,
which results in leak of plasma protein into the extravascular
space (12). However, the mechanisms of VEGF in toluene
diisocyanate (TDI)-induced asthma are unknown. In a murine
model of TDI-induced asthma (13), VEGF level was increased
in bronchial alveolar lavage (BAL) fluid after TDI challenges.
Pre-treatment of VEGF inhibitors could reduce influx of
inflammatory cells, airway hyperresponsiveness (AHR) and
VEGF secretion in BAL fluid, indicating a contribution of
VEGF in TDI-induced asthma. Although there have been a
few studies suggesting a pathogenic contribution of VEGF in
asthma pathology (12, 14, 15), to the best of our knowledge,
this is the first study to evaluate a possible involvement of
VEGF in both airway secretion and serum in acute and chron-
ic airway inflammation of TDI induced asthma patients.
MATERIALS AND METHODS
Subjects
Twenty-four subjects with TDI-induced asthma were en-
rolled. All subjects were withdrawn from the workplace to
avoid further exposure to TDI and received anti-asthmatic
medications according to symptom severity. The subjects were
classified into two groups : group I included 11 newly diag-
nosed asthma patients, and group II included 12 chronic TDI-
asthma patients who had been followed for ≥4 yr with anti-
asthmatic medications. They also had symptoms of asthma
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Acute and Chronic Changes of Vascular Endothelial Growth Factor
(VEGF) in Induced Sputum of Toluene Diisocyanate (TDI)-induced 
Asthma Patients
Vascular endothelial growth factor (VEGF) is a multi-functional cytokine involved in
inflammation, repair and angiogenesis in asthmatic airway. This study aimed to eval-
uate the role of VEGF in immediate bronchoconstriction induced by TDI inhalation,
and in chronic TDI-asthma patients. 11 newly diagnosed TDI-asthma patients (group
I), 12 chronic TDI-asthma patients with persistent asthma symptoms followed for >4
yr and 15 unexposed healthy controls were enrolled. In group I, induced sputum and
serum were collected before and 7 hr after placebo- and TDI-bronchoprovocation
test (BPT). In group II, induced sputum and serum were collected every 2 yr. VEGF
levels were measured by ELISA. There were no significant differences in sputum
and serum VEGF levels between patients and controls. Before and after placebo-
and TDI-BPT, no significant changes were noted in sputum and serum VEGF levels
of group I. In group II patients, sputum VEGF showed variable changes at 1-yr, then
decreased significantly at 2-yr (p<0.05), while serum VEGF showed variable changes
at 2-yr, which decreased significantly at 4-yr (p<0.05). These results suggest that
VEGF may play a minor role in immediate bronchoconstriction after TDI-BPT. In
chronic TDI-asthma, VEGF may be involved to 2 yr after the diagnosis and the con-
tribution may decrease after then.
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Accepted : 12 March 2004requiring anti-asthma medications with complete avoidance.
The diagnosis of occupational asthma had been confirmed by
positive responses to bronchoprovocation tests to TDI (TDI-
BPT). Age matched unexposed healthy subjects were enrolled
as a control group. Atopy was determined by a positive skin
prick test response to at least one common inhaled allergen.
Sera from all subjects were collected at diagnosis and every
2 yr; subjects stopped using inhaled or oral steroids at least
4 weeks before the study. They underwent an interview, chest
radiography, skin prick tests with common inhaled allergens,
lung function measurement and inhalation challenge with
both methacholine, and TDI (80:20=2.4 form: 2.6 form,
Aldrich, Milwaukee, WI, U.S.A.). All subjects gave their
informed consent and the protocol was accepted by the Institu-
tional Review Board of Ajou Medical Center, Suwon, Korea.
Bronchial challenge test with methacholine and TDI
The methacholine bronchial challenge test was done accord-
ing to the method previously described (7). Briefly, aerosols
were generated by a DeVilbiss 646 nebulizer connected to a
DeVilbiss dosimeter driven by compressed air (DeVilbiss Co.,
Doylesttown, PA, U.S.A.). Five inhalations of normal saline
at 5-min intervals were taken followed by a series of succes-
sively doubled doses of methacholine (0.075-25 mg/mL) until
a 20% fall in FEV1 was observed or the maximum dose given.
FEV1 was measured 5-min after the beginning of each set of
inhalations of aerosolized methacholine. The methacholine
PC20 level was determined by interpolation from the dose-
response curve. The TDI-BPT was performed according to
a standardized protocol (7). On the first day, placebo challenge
was performed for one day before the TDI challenge. On the
next day, the subjects were exposed to pure TDI monomers
(Aldrich, U.S.A.) in a small closed room for 5-15 min until
asthmatic symptoms were induced and FEV1 decreased more
than 20% from the baseline value. The concentration of TDI
measured by TLD-1, a toxic gas detector with Cheakey (HAD
Scientific, Lincolnshire, IL, U.S.A.) was less than 20 ppb. FEV1
and FEF25-75% were measured with a spirometer (MultiSPIRO
SX/PC, Tempe, AZ, U.S.A.) immediately before exposure
and every hours for 7 hr after the exposure.
ELISA for VEGF in induced sputum and sera
Sputum was induced using a previously described method
(14) and collected just before (0 min) and after completing
the placebo- and TDI-BPT (420 min after the TDI exposure).
Collected sputum samples were immediately processed as
reported previously (16). The volumes of induced sputum
were determined, and equal volumes of phosphate-buffered
saline-0.5% Tween (PBST) were added. The samples were
then mixed by vortex mixer for 1 min, centrifuged for 20 min.
at 3,000 rpm, and kept frozen at -20℃.
VEGF levels were measured in induced sputum from group
I and II subjects. Sputum was collected twice before the chal-
lenge as baseline value, and at 7 hr after the TDI- and placebo-
challenge tests. 
Sera collection before and after TDI-BPT were completed
in 9 subjects of group I. 
VEGF level in both sputa and sera were measured by ELISA
kit (R&D system, Minneapolis, MN, U.S.A.). Both assays
were performed according to the manufacturer’s guidelines.
The protein content within the sputum was measured by the
Bradford method, and the VEGF levels in the sputum were
presented as ratios to the protein content.
Statistical analysis
ANOVA were done to compare clinical data of two groups
of the study subjects and control. Mann Whitney U test was
applied to compare clinical parameters between group I and
II. The Wilcoxon-Signed rank tests were applied to compare
the changes of VEGF in serum and induced sputum in both
groups. p-value of 0.05 or less was regarded as significant.
RESULTS
Clinical characteristics of the study subjects 
The study subjects and controls were well matched for age
(Table 1). Both group I and II subjects had similar lung func-
tion measurements at baseline. No significant differences were
noted in atopy prevalence, duration of TDI exposure in work-
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Group I (n=11) Group II (n=12) Controls (n=15) p value
Age (yr) 42.0±10.8 44.8±6.87 40.6±4.23 NS 
FEV1 82.8±25.3 79.1±23.7 NA NS*
Atopy* (Presence/Absence) 4/8 4/8 NA NS*
Duration of exposure (months) 92.5±25.5 84.0±8.7 NA NS*
Asthma symptoms before 20.3±15.2 33.0±38.2 NA NS*
diagnosis (months)
VEGF/protein in sputum (baseline, pg/mg) 823.76±676.6 978.66±247.52 1019.3±432.5 NS
VEGF in serum (baseline, pg/mL) 122.76±101.75 307.08±241.80 186.91±132.13 NS*
Table 1. Comparison of VEGF levels in induced sputum and sera between patients and controls
NA, Not available; NS, No statistical significance by ANOVA. NS*: No statistical significance between group I and II.place, and asthma symptom duration before the diagnosis
(p>0.05). Eight of group I had immediate bronchoconstric-
tions after TDI-BPT and three had dual asthmatic responses.
Changes of VEGF in serum and induced sputum of TDI
and placebo challenges
There was a wide variation in the level of VEGF in serum
and sputum in group I subjects. VEGF level of group I tended
to be lower than group II, but no significant differences were
noted among the study subjects as shown in Table 1 (p>0.05).
Fig. 1A demonstrated the changes of VEGF level in induced
sputum of group I patients before and after TDI-BPT. There
were no significant differences in VEGF levels in induced
sputum after TDI-BPT as well as in placebo challenges (place-
bo challenge data was not shown, p>0.05, respectively). Fig.
2B showed changes of VEGF level in serum before and after
TDI-BPT. No significant differences were also noted after
TDI-BPT and placebo challenges (placebo challenge data was
not shown, p>0.05, respectively). 
Changes of VEGF in sera and induced sputa during long
term follow-up period
Fig. 2A shows the changes of VEGF level of group I sub-
jects in induced sputum during 2 yr follow-up period. Spu-
tum VEGF level showed variable changes at 1-yr, which de-
creased significantly at 2-yr after the diagnosis (p=0.03). Fig.
2B shows changes of serum VEGF levels during 4 yr follow-
up period. Serum VEGF level showed variable changes at 2-yr
after the diagnosis (p=0.27), which decreased significantly at
4-yr (p=0.004). There were no significant correlations between
VEGF levels in both sputum and sera with clinical parame-
ters including FEV1 values and airway hyperresponsiveness
to methacholine (data not shown). Also no significant corre-
lation was found between VEGF level and neutrophil and
eosinophil count in the sputum (data not shown). 
DISCUSSION
The pathogenic mechanism of isocyanate-induced occupa-
tional asthma is complicated because several immunological
and non-immunological mechanisms are involved (1). The
previous study (2-6) for analyzing prognostic factors in iso-
cyanate induced asthma patients demonstrated that more
than 50% of the study subjects had persistent asthma symp-
toms, indicating that isocyanate, especially TDI-induced asth-
ma had a poor outcome with abnormal airway function. The
underlying mechanism which explains the poor prognosis is
still unknown. The pathologic findings to suggest airway
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Fig. 2. Changes of sputum (A) and sera (B) VEGF levels in 12 TDI-induced asthma patients (group II). VEGF levels in induced sputum are
presented as the ratio to protein concentation.
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Fig. 1. Changes of VEGF after TDI bronchoprovocation test in in-
duced sputum (A) and serum (B) of TDI asthma patients. No signif-
icant changes are noted in both samples (p>0.05, respectively).362 J.-H. Choi, Y.-J. Suh, S.-K. Lee, et al.
remodeling with increased expression of TGF- 1 was noted
in the airway mucosa of TDI-asthma patients, especially those
who had been complaining of persistent asthma symptoms
(1). These findings may suggest that airway remodeling may
be progressed from an early stage in TDI-asthma patients,
which result in persistent asthmatic symptoms despite anti-
asthmatic medications and complete avoidance. 
VEGF is an endothelial cell-specific mitogen that has been
shown to play a key role in angiogenesis. Furthermore, VEGF
is a potent enhancer of microvascular permeability (17). VEGF
can be produced by a wide variety of inflammatory cells includ-
ing macrophages, neutrophils, and eosinophils and involved
in their activation (12, 13, 16). A mouse model of TDI-asth-
ma study (13) suggested a possible contribution of VEGF in
airway obstruction, migration of inflammatory cells and air-
way hyperresponsiveness development. However, in the pre-
sent study using human samples of TDI-induced asthma
patients, VEGF levels showed no significant changes after
TDI-BPT in both sputum and serum. These findings sug-
gested that VEGF might have a minor role in immediate
bronchoconstriction after TDI exposure in human asthma.
Several investigators suggested contribution of VEGF in chron-
ic asthma and airway remodeling in chronic non-occupation-
al asthma patients. Hoshino et al. (14) demonstrated that
VEGF expression was increased in the asthmatic airway of
chronic asthma patients, which was correlated with airway
caliber and airway hyperresponsiveness. The other study pre-
sented increased VEGF level in induced sputum in compar-
ison to normal controls with imbalance to endothelin (16).
In this study, we found no differences in VEGF level in in-
duced sputum of TDI asthma patients and normal controls,
which was presented in two ways: VEGF level itself and the
ratio of VEGF level to protein concentration. Normal controls
enrolled in this study were defined as non-smoker, non-atopic
healthy controls. And no difference was found between two
groups of asthmatic patients. Correlation coefficient was poor
between VEGF an eosinophil cationic protein level in induced
sputum (data was not shown). To clarify these differences,
further studies will be needed in a larger number of asthmat-
ic patients and controls. However, new findings in this study
was serial observation of VEGF level in the induced sputum
and sera, which demonstrated significant decreases of VEGF
level in airway secretion 2 yr earlier than those in serum. Re-
modeling as a cogent mechanism in chronic asthma must
also take into account matrix proteins, growth factor, insulin
growth factor and possibly anti-apoptotic factors. Thus stud-
ies dealing with single factor such as VEGF are not likely to
explain in the complexity of remodeling. As VEGF was detec-
table in the airway secretion, we can speculate that VEGF
may be involved in airway inflammation/angiogenesis up to
2 yr after the diagnosis in chronic TDI-asthma patients, and
the contribution of VEGF may decrease after then.
In conclusion, the importance of VEGF contribution in
acute bronchoconstriction caused by TDI seems to be low in
TDI induced asthma patients. However, VEGF involvement
in chronic TDI asthma was suggested up to 2 yr after the
diagnosis.
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